Global Newsroom | CSL
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination. Sep 30, 2024 - Head-to-head data, presented at OPTIONS XII for the Control of Influenza Conference, demonstrates advantage of sa-mRNA over conventional mRNA in duration of immune response; Results highlight CSL...
CSL's Garadacimab, a First-in-Class Factor XIIa Inhibitor, Receives …
2023年12月14日 · These regulatory milestones bring CSL one step closer to delivering on our promise to patients with a first-in-class recombinant monoclonal antibody for people living with HAE, a community CSL has been serving for over 40 years, in the U.S. and European Union.
CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial ...
KING OF PRUSSIA, Pa., Feb. 11, 2024 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced top-line results from the Phase 3 AEGIS-II trial evaluating the efficacy and safety of CSL112 (apolipoprotein A-I [human]) compared to placebo in reducing the risk of major adverse cardiovascular events (MACE) in patients following an acute myocardial infarction (AMI).
News Releases | CSL
2022年11月2日 · MELBOURNE, Australia and KING OF PRUSSIA, Pa., Nov. 2, 2022 / PRNewswire / -- At its annual R&D investor briefing today, global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) demonstrated how its growing, innovative pipeline is well-positioned to meet the current and future needs of patients and public health.
News Releases - CSL
KING OF PRUSSIA, Pa., Feb. 26, 2023 / PRNewswire / -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today presented results from the pivotal placebo-controlled Phase 3 VANGUARD clinical trial of garadacimab (CSL312). Garadacimab is CSL's investigational first-in-class monoclonal antibody being developed as a long-term prophylactic ...
CSL Opens New, State-of-the-Art Vaccine Research and …
2023年3月27日 · The site will support CSL's growing R&D portfolio, accelerating the development of next-generation mRNA technology for vaccines . WALTHAM, Mass., March 27, 2023 /PRNewswire/ -- Global biotechnology leader CSL (ASX: CSL; USOTC:CSLLY) today celebrated the official opening of the company's new state-of-the-art research and development (R&D) center in Waltham, Massachusetts.
Japan's Ministry of Health, Labour and Welfare Approves CSL and ...
2023年11月28日 · "Self-amplifying mRNA technology has the potential to be an enduring vaccine option," said Nobel laureate Dr. Drew Weissman, "I look forward to seeing this next generation mRNA technology protect many from COVID-19 and possibly other harmful infectious diseases." "Today's approval marks a historic and exciting milestone as the first sa-mRNA vaccine in the world to be registered, and supports ...
News Releases - CSL
2024年3月19日 · Vafseo® approved by the U.S. FDA for the treatment of anemia due to chronic kidney disease in dialysis-dependent adult patients. CSL Vifor is pleased that its partner Akebia Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Vafseo (vadadustat) tablets for the treatment of... Mar 19, 2024.
News Releases - CSL
2021年10月19日 · CSL (ASX:CSL) is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat hemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies.
News Releases | CSL
2022年10月26日 · In Australia: Jimmy Baker. Communications. Jimmy.Baker@csl.com.au. +61 450 909 211. About Translational Sciences. Translational Sciences is clinical stage, biopharmaceutical company with laboratories based in Phoenix, Arizona. Translational Sciences focuses on developing first-in-class therapeutics for the safe and effective treatment of acute ...